Skip to main content

News & Events

News & Announcements

KaloCyte Welcomes Lyophilization Expert to its Baltimore Headquarters

March 24, 2020, Baltimore, Md. – KaloCyte, Inc., a preclinical-stage healthcare biotechnology company developing ErythroMer, a synthetic, bio-inspired red blood cell substitute for use in settings when stored red blood cells are not available, today announced the hiring of Nivesh Mittal, PhD, as product development scientist.

“Dr. Mittal will lead production of ErythroMer to new heights,” said Elaine Haynes, president and CEO of KaloCyte. “His expertise with lyophilization technologies and nanoparticulate drug delivery systems is a perfect fit for the development of ErythroMer and its readiness for in-human trials within three years.”

Read the full release from KaloCyte.